This is the backstory of: A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density \cite{Recker_2015}
Lilly conducted a clinical trial of Blosozumab, and before it was approved by the FDA, they abandoned it completely.